Park Avenue Securities’s Intra-Cellular Therapies Inc. ITCI Stock Holding History

Park Avenue Securities’s Portfolio ITCI Stock Details ITCI Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q1	–	Sell	-6,293	Closed	-$526K	–	1563
2024 Q4	$526K	Buy	6,293 +1,103	+21%	+$90.6K	0.01%	1046
2024 Q3	$380K	Sell	5,190 -685	-12%	-$51.5K	﹤0.01%	1089
2024 Q2	$402K	Buy	5,875 +318	+6%	+$22.1K	﹤0.01%	1061
2024 Q1	$385K	Sell	5,557 -25	-0.4%	-$1.72K	0.01%	1073
2023 Q4	$400K	Buy	5,582 +37	+0.7%	+$2.13K	0.01%	1005
2023 Q3	$289K	Buy	+5,545	New	+$323K	﹤0.01%	1066
2023 Q1	–	Sell	-4,838	Closed	-$256K	–	1193
2022 Q4	$256K	Sell	4,838 -260	-5%	-$13K	﹤0.01%	1048
2022 Q3	$237K	Buy	+5,098	New	+$266K	﹤0.01%	1005

Other funds holding ITCI

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

PCM

Pentwater Capital Management Naples, Florida $19.3B AUM 58.13% 1-Year Est. Return

HBK Investments Dallas, Texas $9.85B AUM 55.6% 1-Year Est. Return

Norges Bank Oslo, Norway $935B AUM

DKCM

Davidson Kempner Capital Management New York $7.33B AUM 56.47% 1-Year Est. Return

UOC

UBS O'Connor Chicago, Illinois $3.38B AUM 63.08% 1-Year Est. Return

FCM

Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Balyasny Asset Management Chicago, Illinois $77.1B AUM 42.89% 1-Year Est. Return

Park Avenue Securities's ITCI Position: Q1 2025 in Review

Park Avenue Securities sold out of Intra-Cellular Therapies Inc. (ITCI) in Q1 2025, closing a stake of 6,293 shares — an estimated $526K sold.

Park Avenue Securities first reported a position in ITCI in Q3 2022 and held it in 8 quarters. The position peaked at $526K in Q4 2024. 395 funds tracked by Wall St. Rank hold ITCI as of Q1 2025.

Park Avenue Securities reported no remaining Intra-Cellular Therapies Inc. position as of Q1 2025 after selling out during the quarter.
Park Avenue Securities sold 6,293 Intra-Cellular Therapies Inc. shares in Q1 2025, an estimated $526K.
Park Avenue Securities first reported a position in Intra-Cellular Therapies Inc. in Q3 2022 and held it in 8 quarters.
Park Avenue Securities's Intra-Cellular Therapies Inc. position peaked at $526K in Q4 2024.
395 funds tracked by Wall St. Rank held Intra-Cellular Therapies Inc. as of Q1 2025.

Based on Park Avenue Securities's 13F filing for Q1 2025, filed 14 Apr 2025.